

	Monday 25 August		Tuesday 26 August		Wednesday 27 August		Thursday 28 August		Friday 29 August
		07:00-08:45	Breakfast	07:00-08:45	Breakfast	07:00-08:45	Breakfast	07:00-08:45	Breakfast
		09:00 - 09:45	<i>WHERE WE ARE Introductory Lecture 1</i> Radiotheranostics: Current Clinical use and Recent Trials Results Wolfgang Weber, Munich			09:00 - 09:45	Echogenic Biomaterials for Diagnostics and Therapy Inge Herrmann, Zurich	09:00 - 09:30	ROOM CHECK-OUT
		09:45 - 09:50				09:45 - 09:50		09:30-10:15	Presentations Group Work
		09:50 - 10:35	<i>WHERE WE ARE Introductory Lecture 2</i> (Radio-) Tracer Development Margret Schottelius, Lausanne			09:50-10:05	Optimisation of PASylated Ferritin Nanocages for Tumour-specific Imaging in Fluorescence-guided Surgery - Valeria Giacobbo, Milan		
		10:35-10:40				10:05-10:10	First Clinical Experience with the Hybrid Tracer [99mTc]Tc-PSMA-HSG: A Dual-Labeled Radiopharmaceutical for Hybrid Fluorescence & Radioguided Surgery in Prostate Cancer - Johanna Enke, Augsburg	10:15-10:30	coffee break
		10:40-11:10	Coffee Break	09:00 - 12:45	Guided Tour to San Gimignano - the Town of Towers an UNESCO World Heritage Site Ticket required, bus leaves at 8.30h	10:10-10:25	Towards Theranostics-inspired Interventions in Neuropsychiatry with PET-MR-guided Transcranial Focused Ultrasound - Ryan Ash, Stanford	10:30-11:00	What we have learnt, (unresolved) challenges, and what's next? Final Reflections & Discussion
		11:10-11:55	<i>WHERE WE ARE GOING Introductory Lecture 3</i> Expansion of the Field Twan Lammers, Aachen			10:30-10:45		11:00 - 11:15	Awarding & Farewell
		11:55-12:00				10:45-10:50			
		12:00-13:00	Group Work 1			10:50-11:20	Coffee Break		
	ARRIVAL			12:45 - 13:00		11:20-12:05	Mobile Microrobots for Theranostic Applications Metin Sitti, Istanbul	11:30-12:30	Early Lunch
						12:05-12:10			
		13:00 - 14:00	Lunch	13:00 - 14:00	Lunch	12:10-13:00	Group Work 3		
		14:00 - 15:00	Break <i>Optional: Guided Excursion at the Certosa Di Pontignano</i>	14:00-14:45	Tracking Theranostic Cells Paula Foster, London (CA)	14:00-14:45	Break		
				14:45-14:50					
		15:00-15:15	Targeting ALDH1A1 for the Identification and Treatment of Therapy Resistant Cancers - Tim Witney, London	14:50-15:35	Bridging Immune Activation and Imaging through a Modular Nanoparticle Platform Jolanda de Vries, Nijmegen	14:45-15:30	Engineering Magnetotheranostics for Magnetic Particle Imaging Jeff Bulte, Baltimore		
		15:15-15:20				15:30-15:35			
		15:20-15:35	Development of an anti-MET Shark Antibody to Target Non-Small Cell Lung Cancer - Jayden West, Madison			15:35-15:50	Monitoring Biohybrid Tissue-Engineered Heart Valves with Multi-Color MPI and Complementary MRI and US - Elena Rama, Aachen		
		15:35-15:40		15:35-15:40		15:35-15:50			
		15:40-15:55	Radiolabeled PARP Inhibitor-Loaded Polymeric Micelles for Combination Radio-Chemotheranostics - Laura Schäfer, Aachen			15:50-15:55			
		15:55-16:00		15:40-16:15	POSTER PITCHES I	15:55-16:10	Multicolour µCT Enables to Track Therapeutic Stem Cells in a Rat Model of Focal Brain Damage - Clement Capdeville, Lyon		
16:00- 17:15	Opening of Registration	16:00-16:45	From Datasets to Discoveries: A Strategic Vision for AI-enabled Precision Theranostics Lalith Kumar, Munich/Vienna	16:15-16:30	(quick) Coffee Break	16:10-16:15			
	Welcome Coffee & Registration	16:45-17:15	Coffee Break	16:30-17:10	POSTER PITCHES II	16:15-16:30	Theranostic Approach in Parkinson's Disease: Can Small Molecule Pairs Diagnose and Treat? - Ermal Ismailaj, San Sebastián		
				17:10-17:15		16:30-16:35			
17:15 - 17:45	Welcome by the Committee Michal, Neeman, Rehovot	17:15-17:30	Radiolabelled Cholecystokinin-2 Receptor Antagonists Demonstrate Superior Tumour Targeting: Preclinical Studies with Theranostic Implications - Lennart Bohrmann, Basel	17:15-17:30	L-DOS47: A Ureaselimmunoconjugate Capable of Neutralizing the Acidic Tumor Microenvironment in Human Cancer Models - Dimitri Stowbur, Tübingen	17:00-17:45	Beyond Autologous Cells: Designing Synthetic Immune Systems for Precision Cancer Immunotherapy Carl Fidor, Nijmegen		
		17:30-17:35		17:30-17:35					
		17:35-17:50	Next-generation β-galactosidase targeting senescence radiotracers - Francisco Reche-Pérez, Tübingen	17:35-17:50	Oncolytic Virus Therapy as Powerful Promoter of a Combined Tumor Antigen Specific Th1 Cell & Immune Checkpoint Inhibitor (ICI)-based Cancer Immunotherapy - Marc Neumann, Tübingen				
		17:50-17:55		17:50-17:55		17:45-18:00			
17:45 - 18:30	<i>WHERE IT STARTED Welcome Lecture</i> Theranostics - On the Shoulders of Giants Rodney Hicks, Melbourne	17:55-18:10	Decoding Endocrine Resistance: Linking [18F]-FES PET Imaging and Ligand Affinity in Estrogen Receptor-Mutated Breast Cancer - Chloé Jean, Reims						
		18:10-18:15		17:55-18:40	Development of Remote Control CAR T Cells Targeting Solid Tumors Melita Irving, Lausanne				
		18:15-18:30	Theranostic Targeting of the Prostatic Acid Phosphatase (ACP3) with [68Ga]Ga-OncoACP3-DOTA and [177Lu]Lu-OncoACP3-DOTA in Prostate Cancer Patients - Philip Backhaus, Münster						
18:30-18:45		18:30-18:45	Podcast Prep	18:40-18:45		18:00-19:45	Guided Tour Wine Cellars of the Losi Family This includes a 20 minute walk - one way - to the vineyard. Ticket required; limited number of attendees - sorry!		
18:45-19:45	Welcome Reception	18:45-19:45	Dive into Imaging Science Live Podcast Recording with Apéro Guest: Rodney Hicks, Melbourne Paper: Singh, S. et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet	18:45-19:45	Group Work 2				
19:45-20:00		19:45-20:00				19:45-20:00			
20:00	Dinner	20:00	Dinner	20:00	Dinner	20:00	Dinner		